U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 2Na.HO4P
Molecular Weight 142.959
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SODIUM PHOSPHATE P-32

SMILES

[Na+].[Na+].O[32P]([O-])([O-])=O

InChI

InChIKey=BNIILDVGGAEEIG-JCIGTKTHSA-L
InChI=1S/2Na.H3O4P/c;;1-5(2,3)4/h;;(H3,1,2,3,4)/q2*+1;/p-2/i;;5+1

HIDE SMILES / InChI
P-32 is a radioactive isotope of phosphorus with a half-life of 14.29 days. Radioactive decay of P-32 produces beta-particles (electrons) which are able to penetrate tissue at a range of 3-8 mm. Phosphate ion P-32 has many applications in medicine and biology. P32 sodium phosphate was approved by the FDA for the treatment of polycythemia vera, chronic myelocytic leukemia, and chronic lymphocytic leukemia. P32-phosphate may also be used in the palliative treatment of selected patients with multiple areas of skeletal metastases. As metabolic uptake of phosphorus is selectively increased in malignant tissues, P-32 was also used for cancer diagnostics.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
SODIUM PHOSPHATE P 32

Approved Use

P32 sodium phosphate is indicated for the treatment of polycythemia vera and is effective for the treatment of chronic myelocytic leukemia and chronic lymphocytic leukemia. It may also be used in the palliative treatment of selected patients with multiple areas of skeletal metastases

Launch Date

1959
Primary
SODIUM PHOSPHATE P 32

Approved Use

P32 sodium phosphate is indicated for the treatment of polycythemia vera and is effective for the treatment of chronic myelocytic leukemia and chronic lymphocytic leukemia. It may also be used in the palliative treatment of selected patients with multiple areas of skeletal metastases

Launch Date

1959
Primary
SODIUM PHOSPHATE P 32

Approved Use

P32 sodium phosphate is indicated for the treatment of polycythemia vera and is effective for the treatment of chronic myelocytic leukemia and chronic lymphocytic leukemia. It may also be used in the palliative treatment of selected patients with multiple areas of skeletal metastases

Launch Date

1959
PubMed

PubMed

TitleDatePubMed
EANM procedure guideline for 32P phosphate treatment of myeloproliferative diseases.
2007 Aug
Name Type Language
SODIUM PHOSPHATE P-32
ORANGE BOOK  
Common Name English
sodium phosphate (³²P) [INN]
Common Name English
SODIUM PHOSPHATE P 32
MI   USAN  
USAN  
Official Name English
SODIUM PHOSPHATE P32
Common Name English
SODIUM PHOSPHATE P 32 [USAN]
Common Name English
SODIUM PHOSPHATE,P-32 [VANDF]
Common Name English
Sodium phosphate (32 p) [WHO-DD]
Common Name English
SODIUM PHOSPHATE P-32 [ORANGE BOOK]
Common Name English
SODIUM PHOSPHATE, P-32
Common Name English
PHOSPHORUS (32P) SODIUM PHOSPHATE
Common Name English
SODIUM PHOSPHATE P 32 [MI]
Common Name English
SODIUM PHOSPHATE (32P)
INN  
INN  
Official Name English
Classification Tree Code System Code
NCI_THESAURUS C129819
Created by admin on Fri Dec 15 15:41:54 GMT 2023 , Edited by admin on Fri Dec 15 15:41:54 GMT 2023
WHO-ATC V10XX01
Created by admin on Fri Dec 15 15:41:54 GMT 2023 , Edited by admin on Fri Dec 15 15:41:54 GMT 2023
NDF-RT N0000175872
Created by admin on Fri Dec 15 15:41:54 GMT 2023 , Edited by admin on Fri Dec 15 15:41:54 GMT 2023
WHO-VATC QV10XX01
Created by admin on Fri Dec 15 15:41:54 GMT 2023 , Edited by admin on Fri Dec 15 15:41:54 GMT 2023
Code System Code Type Description
EVMPD
SUB76242
Created by admin on Fri Dec 15 15:41:54 GMT 2023 , Edited by admin on Fri Dec 15 15:41:54 GMT 2023
PRIMARY
LACTMED
Sodium Phosphate P 32
Created by admin on Fri Dec 15 15:41:54 GMT 2023 , Edited by admin on Fri Dec 15 15:41:54 GMT 2023
PRIMARY
INN
527
Created by admin on Fri Dec 15 15:41:54 GMT 2023 , Edited by admin on Fri Dec 15 15:41:54 GMT 2023
PRIMARY
DRUG CENTRAL
5036
Created by admin on Fri Dec 15 15:41:54 GMT 2023 , Edited by admin on Fri Dec 15 15:41:54 GMT 2023
PRIMARY
CAS
7635-46-3
Created by admin on Fri Dec 15 15:41:54 GMT 2023 , Edited by admin on Fri Dec 15 15:41:54 GMT 2023
PRIMARY
PUBCHEM
71180
Created by admin on Fri Dec 15 15:41:54 GMT 2023 , Edited by admin on Fri Dec 15 15:41:54 GMT 2023
PRIMARY
ChEMBL
CHEMBL1060
Created by admin on Fri Dec 15 15:41:54 GMT 2023 , Edited by admin on Fri Dec 15 15:41:54 GMT 2023
PRIMARY
DRUG BANK
DB09370
Created by admin on Fri Dec 15 15:41:54 GMT 2023 , Edited by admin on Fri Dec 15 15:41:54 GMT 2023
PRIMARY
EVMPD
SUB04480MIG
Created by admin on Fri Dec 15 15:41:54 GMT 2023 , Edited by admin on Fri Dec 15 15:41:54 GMT 2023
PRIMARY
NCI_THESAURUS
C76284
Created by admin on Fri Dec 15 15:41:54 GMT 2023 , Edited by admin on Fri Dec 15 15:41:54 GMT 2023
PRIMARY
FDA UNII
O181101B5G
Created by admin on Fri Dec 15 15:41:54 GMT 2023 , Edited by admin on Fri Dec 15 15:41:54 GMT 2023
PRIMARY
EPA CompTox
DTXSID30997712
Created by admin on Fri Dec 15 15:41:54 GMT 2023 , Edited by admin on Fri Dec 15 15:41:54 GMT 2023
PRIMARY
SMS_ID
100000137683
Created by admin on Fri Dec 15 15:41:54 GMT 2023 , Edited by admin on Fri Dec 15 15:41:54 GMT 2023
PRIMARY
RXCUI
91559
Created by admin on Fri Dec 15 15:41:54 GMT 2023 , Edited by admin on Fri Dec 15 15:41:54 GMT 2023
PRIMARY RxNorm
MERCK INDEX
m10061
Created by admin on Fri Dec 15 15:41:54 GMT 2023 , Edited by admin on Fri Dec 15 15:41:54 GMT 2023
PRIMARY Merck Index